PDS Biotechnology Corp. (PDSB)
1.12
+0.06
(+5.66%)
USD |
NASDAQ |
Jun 11, 16:00
PDS Biotechnology Research and Development Expense (Quarterly) : 3.457M for March 31, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 3.457M |
| December 31, 2025 | 4.406M |
| September 30, 2025 | 4.576M |
| June 30, 2025 | 4.213M |
| March 31, 2025 | 5.831M |
| December 31, 2024 | 4.530M |
| September 30, 2024 | 6.804M |
| June 30, 2024 | 4.528M |
| March 31, 2024 | 6.704M |
| December 31, 2023 | 7.466M |
| September 30, 2023 | 6.448M |
| June 30, 2023 | 8.005M |
| March 31, 2023 | 5.844M |
| December 31, 2022 | 16.16M |
| September 30, 2022 | 4.353M |
| June 30, 2022 | 3.762M |
| March 31, 2022 | 5.161M |
| December 31, 2021 | 3.389M |
| September 30, 2021 | 3.688M |
| June 30, 2021 | 2.764M |
| March 31, 2021 | 1.413M |
| December 31, 2020 | 2.478M |
| September 30, 2020 | 2.061M |
| June 30, 2020 | 1.414M |
| March 31, 2020 | 1.972M |
| Date | Value |
|---|---|
| December 31, 2019 | 1.348M |
| September 30, 2019 | 1.834M |
| June 30, 2019 | 1.887M |
| March 31, 2019 | 1.03M |
| December 31, 2018 | 0.2669M |
| September 30, 2018 | 0.1941M |
| June 30, 2018 | 0.1686M |
| March 31, 2018 | 0.2011M |
| December 31, 2017 | 10.83M |
| September 30, 2017 | 6.913M |
| June 30, 2017 | 8.975M |
| March 31, 2017 | 7.590M |
| December 31, 2016 | 6.779M |
| September 30, 2016 | 6.724M |
| June 30, 2016 | 5.975M |
| March 31, 2016 | 5.347M |
| December 31, 2015 | 5.266M |
| September 30, 2015 | 6.508M |
| June 30, 2015 | 3.195M |
| March 31, 2015 | 2.871M |
| December 31, 2014 | 2.838M |
| September 30, 2014 | 2.419M |
| June 30, 2014 | 2.124M |
| March 31, 2014 | 1.093M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Abeona Therapeutics, Inc. | 9.555M |
| ACADIA Pharmaceuticals, Inc. | 76.87M |
| Alnylam Pharmaceuticals, Inc. | 364.87M |
| Savara, Inc. | 23.40M |
| Vericel Corp. | 8.104M |